TRT for Pickleball Players Over 45: Safety, Outcomes, and Eligibility, Backed by 5 Studies (2026)

The TRAVERSE trial followed 5,246 men with pre-existing cardiovascular risk factors and found that testosterone therapy did not increase the rate of heart attacks, strokes, or cardiovascular death over a median 33-month follow-up (Lincoff et al., NEJM 2023). For pickleball players over 45 weighing whether to consider TRT, that's the foundational answer to the safety question. The harder question is whether the benefits — measured in lean mass, fat loss, energy, recovery, and sleep — are worth the long-term commitment.

Key Takeaways

• TRAVERSE found no increased cardiovascular risk from TRT in 5,246 high-risk men over a median 33-month follow-up (Lincoff et al., NEJM 2023)
• Endocrine Society 2018 guidelines recommend TRT for men with consistent symptoms AND total testosterone below 264 ng/dL (Bhasin et al., JCEM 2018)
• Average effect: ~1.6 kg fat loss, ~1.6 kg lean mass gain in hypogonadal men (Corona et al., Eur J Endocrinol 2016)
• TRT in men with prediabetes reduced progression to type 2 diabetes (Saad et al., Diabetes Obes Metab 2020)
• Mood and sleep improve within 4 to 6 weeks; body composition takes 12 to 24 weeks
• TRT is a long-term commitment — expect to stay on it for years if results continue
• Florida-only for prescription via PrimeHealth (state medical licensing)

What TRT actually is

TRT (testosterone replacement therapy) is the medical use of bioidentical testosterone to restore physiological levels in men whose own production has dropped below the normal range. It is not a steroid stack. It is not performance enhancement above baseline. The standard clinical aim is to bring total testosterone into the 600 to 900 ng/dL range — close to what most men sat at in their 20s and 30s before the natural decline.

For a 55-year-old playing pickleball four mornings a week, TRT isn't a magic upgrade. It's restoration. If your testosterone is at 320 ng/dL and you used to be at 700, the goal isn't to take you to 1,200. It's to put you back in the range you spent the first 35 years of your life in. The recovery, the lean mass, the energy on court: those weren't extraordinary at 35. They were normal. TRT in men with documented hypogonadism is about getting back to normal, not exceeding it.

The most common formulation is testosterone cypionate, a generic injectable medication that has been in clinical use for decades. Topical gels, creams, and pellets exist as alternatives. Most online clinics, including PrimeHealth, default to injectable cypionate because of its predictability, dosing flexibility, and cost.

Why pickleball players specifically benefit

The hormonal decline behind low testosterone hits the exact systems pickleball stresses:

• Lean muscle mass. Testosterone drives muscle protein synthesis. When it drops, you lose lean mass even if you train, which means less power on shots and weaker stabilizers in shoulders and knees.
• Recovery between sessions. Growth hormone and IGF-1 (which testosterone influences) are central to overnight tissue repair. Lower hormonal signaling means slower recovery from chronic loading.
• Fat loss, especially visceral. TRT preferentially reduces visceral fat (the deep abdominal type), which is what most pickleball players over 50 carry and want to shed.
• Energy and motivation. Testosterone influences dopaminergic pathways tied to drive. Many men report that the biggest immediate improvement on TRT isn't physical — it's motivation. Showing up to the court 4x a week feels less like an effort.
• Chronic injury healing. Testosterone has anti-inflammatory effects and supports collagen synthesis. The chronic rotator cuff, Achilles, or plantar issues that linger in untreated men often improve once hormonal levels are restored.

None of this means TRT will make you a better pickleball player than you were at 35. But for a man whose game has clearly slipped because of hormonal decline (not just skill or training), restoring testosterone removes the headwind.

What the evidence shows: safety

The cardiovascular safety question dominated TRT discourse for over a decade after the FDA added a warning label in 2015 based on observational studies that were later shown to have serious methodological problems.

The TRAVERSE trial settled the question. Published in the New England Journal of Medicine in 2023, TRAVERSE was a randomized, double-blind, placebo-controlled trial in 5,246 men aged 45 to 80 with hypogonadism AND pre-existing cardiovascular disease or high cardiovascular risk. Median follow-up was 33 months.

The headline result: TRT did not increase major adverse cardiovascular events (MACE) compared to placebo. Heart attack and stroke rates were essentially identical. Pulmonary embolism and atrial fibrillation were modestly higher in the TRT arm — which is why standard monitoring includes hematocrit and clotting risk factors.

In response to TRAVERSE, the FDA updated its testosterone product labeling in early 2025 to remove the cardiovascular risk warning that had been in place since 2015. Major medical organizations have followed.

What the evidence shows: outcomes

Beyond safety, the question is what TRT actually does for body composition, metabolic health, and quality of life.

The 2016 Corona et al. meta-analysis (Eur J Endocrinol) reviewed 32 randomized trials and found that TRT in hypogonadal men produced an average reduction in body fat of 1.6 kg and a 1.6 kg gain in lean body mass, with the largest reductions in visceral fat.

Saad and colleagues (Diabetes Obes Metab 2020) followed hypogonadal men with prediabetes on long-term TRT and found significantly reduced progression to type 2 diabetes compared to controls. For pickleball players whose midsection weight has been climbing toward metabolic syndrome, this is one of the most clinically important findings of the past decade.

The overall picture: in men with confirmed hypogonadism, TRT reliably improves body composition, glycemic control, mood, sleep quality, and sexual function. The effect sizes are modest in any single domain but they compound, and they are sustained over years if treatment is maintained.

The realistic timeline

TRT effects appear at predictable intervals. See our breakdown of the TRT effect timeline for full detail, but the short version:

• Weeks 1 to 2: Subtle. Some men report slightly better energy and sleep. Many notice nothing.
• Weeks 3 to 6: Mood and sleep improvements become consistent. Libido begins to return.
• Months 2 to 3: Energy is consistently higher. Workouts feel more productive. Brain fog clears.
• Months 3 to 6: Body composition changes become visible. Lean mass increases, midsection fat begins to shift.
• Month 6 and beyond: Full benefits in mood, energy, body composition. Bone density continues to improve through the first year.

The most common reason men become discouraged with TRT is unrealistic expectations in the first month. The biology of hormonal restoration is gradual — your body spent months or years in deficiency and won't reverse overnight.

When to See a Doctor

The Endocrine Society's 2018 clinical practice guideline (Bhasin et al.) recommends TRT for men with:

1. Consistent symptoms of testosterone deficiency (fatigue, low libido, mood changes, loss of muscle, increased body fat), AND
2. Total testosterone below 264 ng/dL on two separate morning blood draws (clinical labs vary slightly; many specialists use 300 ng/dL as the threshold).

Get evaluated when:

• You have multiple symptoms that fit the low-T pattern
• Your recovery from pickleball has slowed disproportionately
• Belly weight is climbing despite consistent activity
• You have ED or significantly reduced libido
• You're losing muscle even when training

A morning blood test gives you the data to decide. Most men who fit the symptom profile have testosterone in the 250 to 450 ng/dL range — below the optimal threshold but missed by primary care that uses only the lower bound of the reference range as a cutoff.

How PrimeHealth fits in

PrimeHealth is a Florida-based telehealth clinic specializing in men's hormone health, peptide therapy, and medical weight loss for men 40+. A lot of our patients are pickleball players.

Here's how it works:

• At-home blood draw. We ship a lab kit to your door. You collect the sample at home and send it back. Results land in 48 hours.
• TRT. Available to Florida residents only (state medical licensing). If your labs confirm low testosterone, our physicians design a protocol around your numbers and monitor it with regular follow-up labs.
• Peptide therapy. Available nationwide. We work with soft-tissue recovery peptides, growth hormone secretagogues for sleep and lean mass, and GLP-1 protocols like semaglutide for weight management.

If you've been wondering whether TRT is right for your pickleball game and your overall health, knowing your numbers is the first step. Take our free assessment to find out where you stand.

The Bottom Line

TRT in 2026 sits in a different evidentiary place than it did five years ago. The cardiovascular safety question has been answered with the highest-quality evidence available. The body composition, metabolic, and quality-of-life benefits are well-documented in men with confirmed hypogonadism. The remaining variability is individual: dose response, lifestyle integration, and how well the protocol is monitored.

For a pickleball player over 45 with symptoms and lab confirmation, TRT is a reasonable, well-supported option. For a man with normal testosterone and slow recovery, it isn't — the answer there is sleep, training, and time.

Get the labs. Decide from data.

Sources

• Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE trial). N Engl J Med. 2023;389(2):107-117.
• Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
• Corona G, Giagulli VA, Maseroli E, et al. Testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016;174(3):R99-116.
• Saad F, Doros G, Haider KS, et al. Hypogonadal men with moderate-to-severe lower urinary tract symptoms have a more severe cardiometabolic profile and benefit more from testosterone therapy than men with mild lower urinary tract symptoms. Diabetes Obes Metab. 2020.
• Travison TG, Vesper HW, Orwoll E, et al. Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe. J Clin Endocrinol Metab. 2017;102(4):1161-1173.

Last updated: April 2026.